After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BIO belongs to the Healthcare sector of the NYSE while operating in the Medical Devices industry. The current market capitalization of Bio-Rad Laboratories Inc is $8.65B. A total of 0.51 million shares were traded on the day, compared to an average of 254.15K shares.
In the most recent transaction, MICHAEL W CROWLEY bought 1,488 shares of BIO for 275.92 per share on Aug 05 ’25. In a previous transaction on Mar 14 ’25, Crowley Michael sold 3,000 shares at 247.06 per share. BIO shares that EVP, GBL Commercial Operations owns now total 8,171.
Among the insiders who bought shares, Crowley Michael acquired of 3,000 shares on Mar 13 ’25 at a per-share price of $260.00. In another insider transaction, Alles Institute for Medical Re bought 410 shares at $247.66 per share on Mar 11 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BIO has a high of $387.99 and a low of $211.43.
As of this writing, BIO has an earnings estimate of $2.7 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of $3.01 per share and a lower estimate of $2.32. The company reported an EPS of $2.9 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BIO’s latest balance sheet shows that the firm has $869.92M in Cash & Short Term Investments as of fiscal 2021. There were $223.38M in debt and $680.94M in liabilities at the time. Its Book Value Per Share was $263.42, while its Total Shareholder’s Equity was $13.69B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIO is Buy with a score of 3.83.
